Mechanistically, we demonstrated that E2F1 transcriptionally activates TRIP13, which in turn drives the upregulation of the downstream ubiquitin ligase HECTD3.<h4>Conclusion</h4>This study reveals aberrant TRIP13 expression across multiple cancers and its association with immune modulation and tumor aggressiveness. Here, TRIP13 is linked to neoplasm.